Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.31 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.31 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416101 | 0.74 | NPSR1 (0.41) | NPSR1MAPTMEN1KMT2AGAA | |
| SCHEMBL9716878 | 0.70 | HTR2C (0.36) | HTR2CNOTUMKDM1ACNR2 | |
| SCHEMBL28259691 | 0.69 | HTR2C (0.33) | HTR2CKDM1A | |
| SCHEMBL9501829 | 0.68 | MAOB (0.40) | HTR2CKDM1A | |
| SCHEMBL10363387 | 0.68 | HTR2C (0.35) | HTR2CNOTUMKDM1ACNR2 | |
| SCHEMBL19019983 | 0.67 | HTR2C (0.34) | HTR2CNOTUMKDM1A | |
| Benzene SCHEMBL5499312 | 0.67 | MAOB (0.41) | HTR2CKDM1A | |
| SCHEMBL2343756 | 0.64 | HTR2C (0.36) | HTR2C | |
| SCHEMBL7876469 | 0.64 | HTR2C (0.33) | HTR2C | |
| SCHEMBL4615201 | 0.64 | LMNA (0.39) | MEN1KMT2ACYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430023-B1 | SUBSTITUIED UREA RETINOID AGONISTS II | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-6844466-B2 | Alkyl urea retinoid agonists | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | disclosed |
| US-6838472-B2 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1430023-A1 | SUBSTITUIED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| EP-1430024-A1 | ALKYL UREA RETINOID AGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| US-20030158226-A1 | Alkyl urea retinoid agonists | ROCHE BIOSCIENCE, A DIVISION OF SYNTEX (U.S.A.) LLC | 2003-08-21 | — | — | US | disclosed |
| US-20030125383-A1 | Substituted urea retinoid agonists | ROCHE BIOSCIENCE, A DIVISION OF SYNTEX (U.S.A.) LLC | 2003-07-03 | — | — | US | disclosed |
| WO-2003024920-A1 | SUBSTITUTED UREA RETINOID AGONISTS II | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024921-A1 | ALKYL UREA RETINOID AGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125383-A1 | Substituted urea retinoid agonists | RXRA, RXRG, RARG | NPSR1 3182/4885MAPT 1872/4885MEN1 3809/4885 |
| US-20030158226-A1 | Alkyl urea retinoid agonists | RXRG, RXRA, RXRB | NPSR1 3721/4885MAPT 2736/4885MEN1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.